

Contents of *The American Journal of Psychiatry*

July 1995

Volume 152

Editorial

Posttraumatic stress disorder: psychology, biology, and the Manichaeian warfare between false dichotomies. *N.C.A.* 963

Images in Neuroscience

Cortex, IX: Heschl's gyrus and the planum temporale. *Essay by Martha E. Shenton, Robert W. McCarley and Carol A. Tamminga* 966

Special Article

Prodromes and precursors: epidemiologic data for primary prevention of disorders with slow onset. *William W. Eaton, Mohamed Badawi and Beth Melton* 967

Regular Articles

MRI-based measurement of hippocampal volume in patients with combat-related posttraumatic stress disorder. *J. Douglas Bremner, Penny Randall, Tammy M. Scott, Richard A. Bronen, John P. Seibyl, Steven M. Southwick, Richard C. Delaney, Gregory McCarthy, Dennis S. Charney and Robert B. Innis* 973

Low urinary cortisol excretion in holocaust survivors with posttraumatic stress disorder. *Rachel Yehuda, Boaz Kahana, Karen Binder-Brynes, Steven M. Southwick, John W. Mason and Earl L. Giller* 982

Magnetic resonance imaging measurement of gray matter volume reductions in HIV dementia. *Elizabeth H. Aylward, Paul D. Brettschneider, Justin C. McArthur, Gordon J. Harris, Thomas E. Schlaepfer, Jeffrey D. Henderer, Patrick E. Barta, Allen Y. Tien and Godfrey D. Pearlson* 987

Predictors of retrograde amnesia following ECT. *Christina Sobin, Harold A. Sackeim, Joan Prudic, D. P. Devanand, Bobba J. Moody and Martin C. McElhiney* 995

Role of the family in recovery and major depression. *Gabor I. Keitner, Christine E. Ryan, Ivan W. Miller, Robert Kohn, Duane S. Bishop and Nathan B. Epstein* 1002

Vulnerability to psychosis in unipolar major depression: is premorbid functioning involved? *James R. Sands and Martin Harrow* 1009

Rates of seasonal affective disorder in children and adolescents. *Susan E. Swedo, Joanna D. Pleeter, Daniel M. Richter, Cara L. Hoffman, A. J. Allen, Susan D. Hamburger, Erick H. Turner, Emily M. Yamada and Norman E. Rosenthal* 1016

Mental health and choice between managed care and indemnity health insurance. *Thomas V. Perneger, Anne-Françoise Allaz, Jean-François Etter and André Rougemont* 1020

Social consequences of psychiatric disorders, I: educational attainment. *Ronald C. Kessler, Cindy L. Foster, William B. Saunders and Paul E. Stang* 1026

Comparison of standards for assessing patients' capacities to make treatment decisions. *Thomas Grisso and Paul S. Appelbaum* 1033

Hospital use of antipsychotic agents in 1989 and 1993: stable dosing with decreased length of stay. *Ross J. Baldessarini, Judith C. Kando and Franca Centorrino* 1038

Chronic alcoholism and male sexual function. *Raul C. Schiavi, Barbara B. Stimmel, John Mandeli and Daniel White* 1045

Bulimia nervosa in a Canadian community sample: prevalence and comparison of subgroups. *Paul E. Garfinkel, Elizabeth Lin, Paula Goering, Cathy Spegg, David S. Goldbloom, Sidney Kennedy, Allan S. Kaplan and D. Blake Woodside* 1052

Borderline personality disorder symptoms and severity of sexual abuse. *Kenneth R. Silk, Sharon Lee, Elizabeth M. Hill and Naomi E. Lohr* 1059

Images in Psychiatry

John Romano, M.D., 1908–1994. *Essay by John S. McIntyre* 1065

Brief Reports

Pilot study of current factors influencing the choice of psychiatry as a specialty. *Emily K. Lee, Nancy Kaltreider and John Crouch* 1066

Low discharge weight and outcome in anorexia nervosa. *Sinan A. Baran, Theodore E. Weltzin and Walter H. Kaye* 1070

Mortality in anorexia nervosa. *Patrick F. Sullivan* 1073

Attempted suicide among living co-twins of twin suicide victims. *Alec Roy, Nancy L. Segal and Marco Sarchiapone* 1075

A quarter century of suicide in a major urban jail: implications for community psychiatry. *Curtiss J. DuRand, Gary J. Burtka, Edward J. Federman, James A. Haycox and John W. Smith* 1077

Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. *Kees Verburg, Eric Griez, Jaap Meijer and Henk Pols* 1081

Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. *Jonathan Benjamin, Joseph Levine, Mendel Fux, Alex Aviv, Daniel Levy and R. H. Belmaker* 1084

Lack of effect of clonidine on stuttering in children. *Monika Althaus, Harry J. F. Vink, Ruud B. Minderaa, Sineke M. Goorhuis-Brouwer and Menno D. Oosterhoff* 1087

THE TAVISTOCK CLINIC



Foundation Course in Psychoanalytic Group Therapy

This is a one-year course part-time course for professionals working in the public and voluntary sectors who wish to develop an understanding of group processes and their application in the group treatment of adults, adolescents and children. The course is intended as an introduction to the principles and practice of group therapy based on a psychoanalytic approach to understanding the individual and his social world. This course also serves as access to the Diploma/MA in Psychoanalytic Group Therapy, (Ref. M17), which provides a full professional training in the field. Closing date: 14 September 1995.

Information & application forms from:
Academic Services
THE TAVISTOCK CLINIC
120 Belsize Lane London NW3 5BA
or telephone 0171-435 8730
Please quote ref D39

The ECT Handbook

The Second Report of the
Royal College of Psychiatrists'
Special Committee on ECT

Edited by C. P. Freeman



• £14.99 • 176pp. • 1995
• ISBN 0 902241 83 4

Available from the Publications Department,
Royal College of Psychiatrists,
17 Belgrave Square, London SW1X 8PG
(Tel. 0171-235 2351 extension 146)

Epilim Oral Prescribing Information

Presentation Epilim 200 Enteric Coated and Epilim 500 Enteric Coated: Enteric coated tablets containing 200mg, and 500mg Sodium Valproate Ph.Eur. respectively. Epilim Crushable Tablets containing 100mg Sodium Valproate Ph.Eur. Epilim Syrup and Epilim Liquid (sugar free) both containing 200mg Sodium Valproate Ph.Eur. per 5ml. Epilim Chrono 200, Epilim Chrono 300, and Epilim Chrono 500: Controlled release tablets containing a mixture of Sodium Valproate Ph.Eur. and Valproic Acid Fr.P. equivalent to 200mg, 300mg, and 500mg Sodium Valproate respectively. **Indications** Oral formulations of Epilim are indicated for all types of epilepsy. In women of child bearing age Epilim should be used only in severe cases or in those resistant to other treatment. **Dosage and administration** *Adults*; the dose should be titrated at three day intervals until seizure control is achieved. Initially 600mg a day in divided doses increasing in steps of 200mg to a maximum dose of 2500mg per day. *Children over 20kg*; initially 400mg a day in divided doses increasing in steps to a maximum dose of 35mg/kg/day. *Children under 20kg*; initially 20mg/kg/day - the dose may be increased in steps to a maximum of 40mg/kg/day provided that plasma levels are monitored. Epilim Chrono 500 may be given once or twice daily. All other formulations should be given twice daily. **Combination therapy**; levels of Epilim and co-administered anticonvulsants may be affected and optimum dosage is determined by seizure control. **Contraindications, Warnings, etc.** *Contraindications* Active liver disease, family history of severe liver disease, hypersensitivity to valproate. *Side effects* Impaired hepatic function, particularly in children, occasionally leading to hepatic failure - treatment should be withdrawn in patients who suddenly develop symptoms compatible with hepatic disease such as nausea, anorexia, jaundice or malaise. Hyperammonaemia with or without hepatic dysfunction. Blood dyscrasia - impaired platelet function, thrombocytopenia, occasional leucopenia and red cell hypoplasia. Occasionally increased appetite, weight gain, transient hair loss, behavioural disturbances, alterations to the menstrual cycle and pancreatitis. Symptoms of intoxication include ataxia, tremor, and stupor. **Drug interactions** Epilim has significant interactions with phenytoin, lamotrigine and other anticonvulsants. Epilim may potentiate the effects of neuroleptics, MAOIs and other antidepressants, anticoagulants and salicylates. Cimetidine may inhibit the metabolism of Epilim. Epilim has no effect on the efficacy of oral contraceptives. **Pregnancy** An increased incidence of congenital abnormalities has been demonstrated in offspring born to mothers with epilepsy both untreated and treated, including those treated with sodium valproate. Neural tube defects have been reported in about 1% of offspring of women who have received valproate during the first trimester of pregnancy. Pregnancies should be screened for neural tube defects by estimation of alpha-fetoprotein and ultrasound. Folate supplementation has been shown to reduce the incidence of neural tube defects in the offspring of high risk women. **Legal category** P.O.M. **Further information** Epilim is hygroscopic - tablets should not be removed from their foil until they are used. Epilim Chrono is recommended in cases where plasma valproate levels are being measured on account of its pharmacokinetics. The effective therapeutic range for valproate is 40-100mg/l (278-694 micromol/l). **Product Licence Numbers** Epilim 200 Enteric Coated 11723/0018, Epilim 500 Enteric Coated 11723/0020, Epilim 100mg Crushable Tablets 11723/0017, Epilim Syrup 11723/0025, Epilim Liquid 11723/0024, Epilim Chrono 200 11723/0078, Epilim Chrono 300 11723/0021, Epilim Chrono 500 11723/0079. **NHS Cost** Epilim 200 Enteric Coated 100 tablets £6.42, Epilim 500 Enteric Coated 100 tablets £16.04, Epilim 100mg Crushable Tablets 100 tablets £3.89, Epilim Syrup 300ml £5.89, Epilim Liquid 300ml £5.89, Epilim Chrono 200 100 tablets £7.70, Epilim Chrono 300 100 tablets £11.55, Epilim Chrono 500 100 tablets £19.25. **Address:** Sanofi Winthrop Ltd., One Onslow Street, Guildford, Surrey GU1 4YS. **Telephone:** (01483) 505515 **Fax:** (01483) 35432. Epilim, Epilim Chrono and the Chrono device are registered trade marks. **Date of preparation** April 1995.

References:

1. Chadwick D., *J. Neurol. Neurosurg. Psychiatry* 1994; 57: 264-277.
2. Gilham R.A., *Epilepsy Res.*, 1990; 7: 219-225.



Give someone with epilepsy a future to look forward to

People with epilepsy have the same aspirations as anybody else. What they need is a treatment which allows them to fulfil their potential.


Whatever the type of epilepsy, Epilim Chrono can help. Effective both in generalized and partial seizures,¹ it is well tolerated (particularly with regard to cognitive function)², and offers patients the convenience of once-daily dosing.*

It helps people with epilepsy get on with their lives today, and look forward to tomorrow.

A young girl in a white tutu and ballet slippers stands looking at a large, arched mirror. The mirror reflects a ballerina in a white tutu performing a dance move. The scene is set against a plain white background.

*500mg Tablets
Epilim **CHRONO**
Sodium Valproate Ph. Eur.
Valproic Acid Fr.P Controlled Release

Once-daily management
for all forms of epilepsy



LUSTRAL*

sertraline

**Builds a successful recovery
from depression with anxiety**

Further information is available on request from:
Richborough* Pharmaceuticals or Invicta* Pharmaceuticals
Divisions of Pfizer Limited, Sandwich, Kent.
Legal Category: POM *Trade Mark

66214 Dec 94

